Comparison of overall survival for non-small cell lung cancer patients

Patients with early stages of NSCLC are typically treated with surgery, but those with stage IIIA present more of a challenge because they are such a diverse group. However, new research shows that patient's with stage IIIA NSCLC who receive surgery, lobectomy in particular, have increased overall survival compared to those who received chemoradiation alone -- those receiving lobectomy plus chemoradation had survival rates that were higher than previously reported as well.

Read the whole article on Science Daily

More from Science Daily